Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

254 results about "Coli cell" patented technology

Escherichia coli or E. coli is a bacterium that can be found in human intestines. Scientists have studied E. coli very well, and know more about how E. coli cells work than any other organism.

Preparation method for soluble truncated human tumor necrosis factor-related apoptosis inducing ligand (TRAIL) active protein

The invention provides a preparation method for a soluble truncated human tumor necrosis factor-related apoptosis inducing ligand (TRAIL) active protein, comprising the following steps of: (A) designing and synthetizing an oligomerization deoxyribonucleic acid (DNA) single-stranded segment according to the amino acid sequence of the human TRAIL protein issued by a Genebank by the preference of a bacterium genetic code; (B) synthetizing a complete double stranded DNA by three-time polymerase chain reaction (PCR); (C) carrying out amplification by utilizing a T-carrier, and inserting the amplified double stranded DNA segment into an expression carrier and screening a positive transformant; (D) expressing the truncated human TRAIL protein in escherichia coli at low temperature; (E) purifying the protein by using a three-step method; and (F) determining the truncated TRAIL protein. The invention realizes that the truncated human TRAIL protein is efficiently expressed in an escherichia coli cell and a purification preparation technique thereof and overcomes the problem that an infusible inclusion body is easy to form in the prior art. The method has the advantages of simple operation, short fermentation time and easy purification, and moreover, the protein is ensured not to have any modification, and the protein reaches electrophoretically pure. The invention can be directly used for the research work of biochemistry and molecular biology and the oncology and the preclinical stage of tumor treatment or the development of clinical drugs.
Owner:HUBEI UNIV

High pressure treatment of aggregated interferons

High pressure to treat aggregated interferons, particularly recombinant human interferon-β, to reduce the aggregate content of interferon material. Highly pure, soluble monomeric recombinant interferon-β is prepared in representative embodiments. Multiple strategies may be used in combination that make nonglycosylated IFN-β more amenable to high pressure treatment. It has been found that refolding yields of high pressure treatment can be significantly improved by use of a combination of strategies, including, or example a pre-treatment of the IFN-β that involves solubilizing and then precipitating the protein. This pre-treatment is particularly effective with respect to recombinant IFN-β inclusion bodies recovered from host cells such as E. coli cells. According to another strategy, refolding under high pressure is much more effective when the refolding reagent incorporating the IFN-β incorporates a zwitterionic surfactant and / or a cholate salt. When a solubilization and precipitation pre-treatment is used, the effectiveness of the high pressure treatment is further enhanced when the refolding reagent incorporating the protein incorporates a disulfide shuffling chemistry such as cysteine / cystine. According to still yet another strategy, high pressure treatment is more effective when using atypically high treatment pressures. When coupled with purification techniques, these strategies singly or in combination provide a low aggregate or substantially aggregate free, biologically active solution. Biologically active solutions comprising nonglycosylated interferon, said interferon comprising less than about 5 weight percent of protein aggregation has been found to exhibit improved PK / PD characteristics.
Owner:NURON BIOTECH

Astaxanthin synthetic gene recombinant plasmid as well as preparation method and application of astaxanthin synthetic gene recombinant plasmid

The invention discloses an astaxanthin synthetic gene recombinant expression plasmid pET-Ast with a base sequence as shown in SEQ ID NO: 1. The invention also discloses a preparation method of the recombinant expression plasmid pET-Ast, an application of the recombinant plasmid pET-Ast to the detection of astaxanthin synthetase activity of a target receptor, and an application method. After the astaxanthin synthetic gene recombinant expression plasmid pET-Ast provided by the invention is introduced to an Escherichia coli BL21 strain, the accumulation of astaxanthin in a cell body of Escherichia coli is successfully realized, so that an astaxanthin production strain can be accurately and rapidly established. The preparation method of the astaxanthin synthetic gene recombinant expression plasmid pET-Ast is simple and convenient, easy to operate and low in cost. By using the method disclosed by the invention, a gene sequence to be detected in the target receptor can be replaced with a related gene sequence in the recombinant expression plasmid pET-Ast through digestion and connection, and then, the function of a gene to be detected in the target receptor can be simply and effectively detected and verified through detecting whether the astaxanthin is accumulated in a host cell body.
Owner:HEBEI UNIVERSITY

High pressure treatment of aggregated interferons

High pressure to treat aggregated interferons, particularly recombinant human interferon-β, to reduce the aggregate content of interferon material. Highly pure, soluble monomeric recombinant interferon-β is prepared in representative embodiments. Multiple strategies may be used in combination that make nonglycosylated IFN-β more amenable to high pressure treatment. It has been found that refolding yields of high pressure treatment can be significantly improved by use of a combination of strategies, including, or example a pre-treatment of the IFN-β that involves solubilizing and then precipitating the protein. This pre-treatment is particularly effective with respect to recombinant IFN-β inclusion bodies recovered from host cells such as E. coli cells. According to another strategy, refolding under high pressure is much more effective when the refolding reagent incorporating the IFN-β incorporates a zwitterionic surfactant and / or a cholate salt. When a solubilization and precipitation pre-treatment is used, the effectiveness of the high pressure treatment is further enhanced when the refolding reagent incorporating the protein incorporates a disulfide shuffling chemistry such as cysteine / cystine. According to still yet another strategy, high pressure treatment is more effective when using atypically high treatment pressures. When coupled with purification techniques, these strategies singly or in combination provide a low aggregate or substantially aggregate free, biologically active solution. Biologically active solutions comprising nonglycosylated interferon, said interferon comprising less than about 5 weight percent of protein aggregation has been found to exhibit improved PK / PD characteristics.
Owner:NURON BIOTECH

Method for isolation and identification of Escherichia coli 0157:H7 and plating media for said process

A solid plating medium for the presumptive detection of Escherichia coli 0157:H7 which comprises (1) an ingredient which promotes growth of Escherichia coli cells under incubation, (2) an ingredient which inhibits growth of gram positive microorganisms under incubation, (3) an ingredient that inhibits growth of Proteus sp. under incubation, (4) an ingredient which inhibits the growth of strains of Escherichia coli other than Escherichia coli 0157:H7 under incubation, (5) a carbohydrate medium that under incubation is not fermented by Escherichia coli 0157:H7 but which is fermented by other microorganisms including other strains of Escherichia coli, (6) a pH indicator dye which changes the plating media to a first color when the pH of the medium changes, (7) a chromogenic beta-galactosidase substrate that produces precipitate of a second color responsive to beta-galactosidase, the first color contrasting with the second color and the first and second colors blending to produce a third color which contrasts with the first and second colors, and (8) a mass of agar sufficient to solidify the mixture. Also, the method of detecting the presence of Escherichia coli 0157:H7 comprising inoculating the solid plating medium set forth above with a test sample containing Escherichia coli including Escherichia coli 0157:H7, then incubating said plating medium for a period sufficient to obtain colonies of microorganisms and generating one or more of the colors produced by the plating medium, and then examining the surface of the medium for the presence of colonies of the second color.
Owner:R&F PROD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products